SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics PLC reports a successful fiscal year with revenues reaching £1.2m, up from £0.1m, following the acquisition of Dermatonics and growth in AxisBiotix-Ps sales. The company has seen positive results from its acne study and is on track with its commercialization plans, with a notable reduction in cash burn post-acquisition. The firm’s strong performance and strategic partnerships, such as with the Umesh Modi Group, are setting a positive outlook for the upcoming year.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
